ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas ASCO Guidelines ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.

Frontline EGFR exon 20, adjuvant RET, and long-term ALK data are expected to sharpen biomarker-driven selection and potentially reset standards in defined molecular NSCLC subsets. PD-1/VEGF bispecific ...

The singer's ex-husband, Nick Lachey, recently revealed that her children were in a "separate class of service" on a recent flight they were both on Jessica Simpson/Instagram Jessica Simpson clarified ...

Mark Fuhrman, the former Los Angeles police detective who became infamous as one of the lead officials investigating O.J. Simpson after the deaths of his ex-wife, Nicole Brown, and her friend Ron ...

Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T candidate that would become Carvykti—now the world’s most successful cell therapy—Legend ...

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. And the first-in-class PD-1xVEGF bispecific didn’t disappoint—at least on its ...

For us, the big story at ASCO is not really one abstract in isolation. It’s whether the meeting gives us more evidence that by specifics of becoming a major modality in solid tumors and not just an ...

Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning. By ...